Ahmed Bennis/X
Sep 28, 2025, 11:10
Mortality Reduction With SGLT2 + GLP-1 Therapy in T2D and Cardiovascular Disease
Ahmed Bennis, Professor of Cardiology at Ibn Rochd University Hospital, shared a post on X:
” SGLT2 inhibitors and GLP-1 receptor agonists. impact on mortality in diabetic patients with cardiovascular disease.
In patients with T2D and ASCVD, treatment with SGLT2-I and GLP-1RA, especially in combination, is associated with a substantial reduction in mortality.”
Read more here.
Stay updated with Hemostasis Today.
-
Jul 23, 2026, 19:17Diego López Santos: Donation after Donation, I Just Reached 100
-
Jul 23, 2026, 19:11Jecko Thachil: Chlorosis May Have Represented Iron Deficiency in the 19th Century
-
Jul 23, 2026, 15:58Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
-
Jul 23, 2026, 15:43Lorna Knight: The Next Frontier in Sickle Cell Disease Is Access
-
Jul 23, 2026, 15:29Ben Kleinstiver: Overcoming a Major Barrier to Scalable Gene Editing
-
Jul 23, 2026, 15:28Modernizing DIC Diagnosis in Cirrhosis: Building an International Registry for Precision Hemostasi
-
Jul 23, 2026, 14:32Saneha Anjum Shaikh: Why Antibody Screening Must Be Standard Practice in Modern Blood Banking
-
Jul 23, 2026, 14:00Ron Vezina: Canadian Blood Services Issues Urgent Donation Appeal
-
Jul 23, 2026, 13:46Sebastian Szmit: Understanding Troponins in Modern Cardio-Oncology